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The main barrier to the development of an effective RNA interference (RNAi) therapy is the 
lack of a suitable delivery vector. Modified cyclodextrins have emerged in recent years for the 
delivery of siRNA. In the present study, a folate-targeted amphiphilic cyclodextrin was 
formulated using DSPE-PEG5000-folate to target prostate cancer cells. The fusogenic peptide 
GALA was included in the formulation to aid in the endosomal release of siRNA. Targeted 
nanoparticles were less than 200 nm in size with a neutral surface charge. The complexes were 
able to bind siRNA and protect it from serum nucleases. Incubation with excess free folate 
resulted in a significant decrease in the uptake of targeted nanoparticles in LNCaP and PC3 
cells, both of which have been reported to have differing pathways of folate uptake. There was 
a significant reduction in the therapeutic targets, ZEB1 and NRP1 at mRNA and protein level 
following treatment with targeted complexes. In preliminary functional assays using 3D 
spheroids, treatment of PC3 tumours with targeted complexes with ZEB1 and NRP1 siRNA 
resulted in more compact colonies relative to the untargeted controls and inhibited infiltration 
into the Matrigel™ layer.  
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1. Introduction 
Prostate cancer is the most prevalent cancer diagnosed in men of the western world (in the US, 
an estimated 220,000 new cases were diagnosed in 2015), with current treatments for the 
metastatic disease offering only a modest increase in survival (Siegel et al., 2015). Since its 
discovery, RNA interference (RNAi) has been considered as an effective potential therapeutic 
for a wide range of diseases, including, but not limited to, cancer. The uptake and targeted 
delivery of the large, anionic siRNA is the main barrier to the development of effective RNAi 
therapeutics (Wittrup and Lieberman, 2015). In 2003, the first proof of principle of RNAi 
therapeutics emerged where siRNAs were shown to successfully treat disease in an in vivo 
model where the delivery of naked Fas siRNA protected mice from autoimmune hepatitis 
(Song et al., 2003).   
Cyclodextrins (CD) are a family of cyclic oligosaccharides with a history of use as 
pharmaceutical excipients (Jambhekar and Breen, 2016a, b). As well as acting as solubilizers 
and stabilizers in drug formulations, modified cyclodextrins can act as carriers of large complex 
molecules, such as nucleic acids and proteins (A do Carmo et al., 2014; Aranda et al., 2013; 
Meredith et al., 2015). In fact, the first example of targeted delivery of siRNA in humans was 
using a cyclodextrin containing polymer (CDP) as a delivery vector (Davis, 2009). In this 
study, CDP vectors containing siRNA targeting M2 subunit of ribonucleotide reductase 
(MMR2) were targeted to tumours using the transferrin moiety, termed CALAA-01 (Davis, 
2009). Since the emergence of CALAA-01, cyclodextrins have emerged as an effective vector 
for delivering siRNA in a variety of diseases including prostate cancer and neurological 
disorders (Evans et al., 2015; Fitzgerald et al., 2016; Guo et al., 2012; O’Mahony et al., 2012b).  
In a recent study, an amphiphilic CD formulated with DSPE-PEG5000-folate to target PSMA in 
prostate cancer cells resulted in a significant reduction in RelA mRNA (knockdown of RelA 
has previously been shown to reduce the metastatic potential of PC3 cells (Evans et al., 2015)) 
in PSMA-positive cells compared with non-silencing and untargeted controls (Evans et al., 
2016b). The incorporation of DSPE-PEG5000-folate into pre-formed CD.siRNA nanoparticles 
resulted in an improved pharmacokinetic profile of siRNA, with significant increases in half-
life (t1/2), area under the curve (AUC) and clearance compared with naked siRNA (Evans et al., 
2016b). 
Following successful uptake and internalisation of siRNA containing nanoparticles into cells, 
inefficient endosomal escape can hinder any therapeutic benefit. GALA is a 30 amino acid 
endosomal escape peptide (WEAALAEALAEALAEHLAEALAEALEALAA) that is derived from 
viral proteins that enhances endosomal release following its uptake (Li et al., 2004; Parente et 
al., 1990). The composition of the GALA peptide is repetitive units of Glu-Ala-Leu-Ala. 
Subbarao et al demonstrated that at a low pH (such as the environment of the endosome), the 
GALA peptide transitions from a random coil structure to a α-helical structure, which exposes 
a hydrophobic face in the peptide. This transition was confirmed by circular dichroism. 
Association of the GALA peptide with a bilayer at low pH was confirmed by measuring the 
shift in fluorescence of a tryptophan residue at the terminal end of the peptide following 
incubation at pH 5 (Subbarao et al., 1987). The addition of GALA to cationic nanoparticles has 
been shown to improve their endosomal escape (Simoes et al., 1998; Simoes et al., 1999a; 
Simoes et al., 1999b). 
Epithelial to mesenchymal transition (EMT) is a fundamental developmental process that 
occurs during embryogenesis (Hay, 1995). This process has been well documented as being 
reactivated in many disease states including cancer, with EMT shown to regulate cancer 
metastasis and chemoresistance (Fischer et al., 2015; Yao et al., 2011; Zheng et al., 2015). The 
transcription factor zinc finger E-box-binding homeobox 1 (ZEB1) has been shown to induce 
EMT by direct downregulation of E-cadherin (Zhang et al., 2015). Neuropilin-1 (NRP-1) is a 
transmembrane glycoprotein that interacts with members of the VEGF family to promote 
angiogenesis (Graziani and Lacal, 2015; Pellet-Many et al., 2008). NRP1 expression has been 
shown to be upregulated in metastatic prostate cancer compared with localized prostate cancer 
(Latil et al., 2000; Yacoub et al., 2009). Consequently, the silencing of these genes using siRNA 
may have significant therapeutic potential. 
Previously, a folate targeted CD nanoparticle (NP) was formulated for siRNA delivery to 
prostate cancer (Evans et al., 2016b). However, the CD used in this case was an “inverted” 
SC8CDcysteamine which contained cationic amine groups on its primary face and C8 lipophilic 
chains on the secondary face (O’Mahony et al., 2012a). For the current study, an alternative 
amphiphilic SC12CDclickpropylamine CD (cationic groups on the secondary face and C12 on 
the primary face) was used, which has shown great therapeutic potential for siRNA delivery in 
a wide variety of disease states including Huntington’s disease and inflammatory bowel disease 
(Godinho et al., 2013; McCarthy et al., 2013). The primary aim of this study was to formulate 
a folate-targeted CD with the fusogenic peptide GALA in order to facilitate enhanced 
endosomal escape. DSPE-PEG5000-folate and the GALA peptide were post-inserted into 
preformed CD.siRNA complexes. The physicochemical properties of the nanoparticles were 
assessed as well as their ability to achieve targeted delivery in prostate cancer cells in vitro. 
The complexes were used to deliver ZEB1 and NRP1 siRNA into prostate cancer cells and 
knockdown was assessed using RT-PCR and western blot analysis. Preliminary functional 
studies were carried out by assessing the invasive capacity of 3D PC3 spheroids following 
knockdown of ZEB1 and NRP1. 
2. Materials and methods 
2.1.Materials 
GALA peptide was purchased from AnaSpec (Fremont, CA). ZEB1, NRP1 and negative 
control siRNA were purchased from ThermoFisher Scientific (Waltham, MA). FLuciferase 
siRNA was custom synthesized by IDT (Coralville, IA) with the following sequence: (sense 
5’-GGGGGACGAGGACGAGCACUTC-3’). Negative control 6-carboxyfluorescein (6-
FAM)-labelled siRNA was purchased from Sigma Aldrich (St. Louis, MO)  Amphiphilic 
SC12CDclickpropylamine cyclodextrin was synthesized as previously described (O’Mahony et 
al., 2012b). DSPE-PEG5000-folate (DPF) and DSPE-PEG5000-methyl (DPM) were purchased 
from Nanocs (New York, NY). 
2.2.Preparation of CD.siRNA nanoparticles 
CD and siRNA nanoparticles at a mass ratio (MR) of CD:siRNA of 20:1 were prepared as 
previously described (Evans et al., 2015). Briefly, siRNA and CD were mixed at MR20 at room 
temperature, vortexed lightly for 10-15 sec, and left to form electrostatic interactions for 25-30 
minutes. DSPE-PEG5000 reagents (i.e. DSPE-PEG5000-methyl and DSPE-PEG5000-folate) were 
dissolved in water to 1 mg/ml. GALA peptide was dissolved in 1% NH
4
OH to 0.25 mg/ml. 
DSPE-PEG5000 reagents and GALA were mixed together and added to preformed CD.siRNA 
nanoparticles by the post-insertion method previously reported [REF]. Resulting mixtures were 
heated to 60°C for 15 mins at 500 rpm in a thermomixer. The exact composition of each 
formulation is described in in Table 1.  
2.3.Particle size and zeta potential (ζ) 
Particle size and zeta potential (ζ) of cyclodextrin nanoparticles were measured using a 
Malvern Zeta Sizer (Malvern, Worcestershire, UK) as previously described (Evans et al., 
2016b). 
2.4.Transmission electron microscopy (TEM) 
Complexes were made as described above and added to 400 mesh carbon-film copper grids 
(Agar Scientific, Essex, UK). Grids were stained with 2 % (w/v) uranyl acetate, left to dry and 
images taken using a JEOL 2000 FXII transmission electron microscope (Jel Ltd., Tokyo, 
Japan). 
2.5.Binding Assay 
Complexes were formed as above and run on a 1.5 % agarose gel at 120 V in Tris/Borate/EDTA 
(TBE) for 30 minutes supplemented with 0.06 % v/v SafeView nucleic acid stain (NBS 
Biologicals). UV light was used to visualize unbound siRNA. 
2.6.Assessment of nanoparticles in physiological conditions 
Serum stability studies were carried out in 10 % FBS at 0 min, 3 min, 15 min, 1 h, 4h and 8 h 
as previously described (Evans et al., 2016b). For the aggregation study, nanoparticles were 
incubated in 90 % optiMEM® for up to 4 h. The count rate of the solutions at each of the time 
points was determined using a Malvern Zeta Sizer (Malvern, Worcestershire, UK). 
2.7.Cell culture 
PC3 and LNCaP cells were provided by the Australian Prostate Cancer Research Centre 
Queensland (APCRC-Q), purchased previously from the American Type Culture Collection 
(ATCC, Manassas, VA, USA) and maintained in phenol-red free RPMI 1640 supplemented 
with 5 % FBS. Both cell lines were grown in the Forma Series II Water Jacketed CO2 incubator 
(Thermo Electron Corporation, Waltham, Massachusetts) at 37°C with 5 % CO2 and 95 % 
relative humidity. 
2.8.MTT assay 
1 x 104 PC3 and LNCaP cells were seeded into 96 well plates 24 h prior to transfection. Cells 
were transfected with cationic CD (CCD), CD-DSPE-PEG5000-Folate-GALA (CD-F-G) and 
CD-DSPE-PEG5000-Methyl-GALA (CD-M-G) complexes for 24 h. Following this time, 
complexes were removed and cells were incubated with MTT solution (0.5mg/ml) for 4 hours. 
Resulting formazoan crystals were dissolved in DMSO and absorbance was read using a 
multiplate reader at 590 nm (Perkin Elmer – Wallac Victor2™ 1420 multiplate counter). 
2.9.Competition assay 
1 x 104 PC3 and LNCaP cells were seeded into a black 96-well plate. Cyclodextrin complexes 
with 50 nM 6-FAM-labelled siRNA were formulated as described above. Cells were pre-
incubated with 2.5 mM folic acid for 1 hour prior to the addition of the complexes. Complexes 
were left on cells for 4 h. Cells were washed twice with PBS to remove any unbound 
complexes. Cell uptake was determined by measuring fluorescence intensity using a Perkin 
Elmer Victor2 1420 fluorescent plate reader (excitation 485 nm, emission 535 nm).  
2.10. Luciferase assay 
1 x 104 PC3Luc cells (engineered to express luciferase) were seeded in opaque white 96-well 
plates (Corning Inc., NY) 24 h prior to transfection. Cells were transfected with either 
Lipofectamine2000 (LIPO) or CD complexed with 100 nM negative control siRNA or 
luciferase siRNA for 48 h. D-luciferin (PerkinElmer, Waltham, MA) was added to cells and 
luminescence was determined using a multiplate reader at 560 nm (Perkin Elmer – Wallac 
Victor2™ 1420 multiplate counter). 
2.11. 3D spheroid invasion assay 
1 x 10 3 PC3 cells were seeded onto the surface of undiluted Matrigel™ in phenol-red free 
RPMI1640 containing 2.5 % (v/v) Matrigel™. Following the formation of spheroids (typically 
3-4 days), cells were treated with CD-F-G and CD-M-G nanoparticles at t= 0 h and t= 48 h at 
a final siRNA concentration on 100 nM. 
2.12. Quantitative real-time (RT) PCR 
24 h prior to transfection, 5 x 104 PC3 and LNCaP cells were seeded in 24 well plates. Cells 
were transfected with CD.siRNA complexes for 24 h and RNA was extracted using Direct-
zol™ RNA kit (Zymo Research, Australia). 300 ng of RNA was used to synthesize cDNA 
using SensiFAST™ cDNA synthesis kits (Bioline, UK). RT-PCR was carried out using SYBR 
Green (Applied Biosystems, Foster City, CA) and ViiA 7 Real Time PCR system (Applied 
Biosystems, Foster City, CA). Primers targeting ZEB1 (Primer sequence; forward: 
CAACTACGGTCAGCCCT, reverse: GCGGTGTAGAATCAGAGTC), NRP1 (Primer 
sequence; forward: AGGACAGAGACTGCAAGTATGAC, reverse: 
AACATTCAGGACCTCTCTTGA) and the house keeping gene RPL32 (Primer sequence; 
forward: GCACCAGTCAGACCGATATG, reverse: ACTGGGCAGCATGTGCTTTG) were 
used and gene expression determined by the comparative Ct method. 
2.13. Western blot analysis 
24 h prior to transfection, 2.5 x 105 PC3 cells were seeded in 6 well plates. Cells were 
transfected with CD.siRNA complexes for 48 h and lysed using RIPA (Radio-
Immunoprecipitation Assay) buffer with protease inhibitor cocktail (P8340) (Sigma). Protein 
concentrations were quantified using the BCA assay. 30μg of the total protein was loaded onto 
a 4-12% gradient BOLT® gel (Thermo Fisher Scientific, Waltham, MA) and run at 150 V after 
which proteins were transferred onto a nitrocellulose membrane. Western blotting was carried 
out using antibodies to NRP1 (sc-7239, Santa Cruz Biotechnology), ZEB1 (3396, Cell 
Signalling Technologies) and β-actin (sc-7239, Santa Cruz Biotechnology). Signals were 
detected using Infrared secondary antibodies and the Licor Odyssey® Infrared imaging system 
(Lincoln, NE). 
2.14. Statistical analysis 
Data were expressed as mean ± standard deviation (SD) of at least triplicate samples. One-way 
Analysis of Variance (ANOVA) was performed to test the significance of differences in three 
or more groups followed by Tukey’s Post-Hoc test and a two-tailed unpaired student t-test was 
used to compare significance of differences in two groups. In all cases, P < 0.05 was considered 
to be statistically significant. All graphs and statistical calculations were prepared using 
GraphPad Prism 5 (San Diego, CA). 
3. Results and discussion 
3.1 CD-F-G nanoparticles display favourable physicochemical properties and are 
capable of binding and protecting siRNA from serum nucleases. 
Four different cyclodextrin formulations were investigated in this study: 
Formulation one was a cationic amphiphilic CD complexed with siRNA (hereafter referred to 
as CCD).  
Formulation two was a targeted NP containing CCD co-formulated with a blend of DSPE-
PEG5000-folate (DPF) and GALA peptide (hereafter referred to as CD-F-G).  
Formulation three was a targeted NP containing CCD co-formulated with DSPE-PEG5000-
folate (DPF) (hereafter referred to as CD-F) 
Formulation four was the untargeted NP control containing CCD with DSPE-PEG5000 (DPM) 
and GALA (referred to as CD-M-G).  
Screening studies were performed in order to determine the optimal molar ratio of CD:DSPE-
PEG:GALA (Supplementary Table 1). The exact composition, particle size, zeta potential 
and PDI of each formulation is given in Table 1.
 
The amphiphilic CD used in this study has previously been shown to be capable of fully 
complexing siRNA from mass ratio 5 (MR 5) and above (Godinho et al., 2013). It was therefore 
necessary to test whether the addition of DSPE-PEG5000 alone or in combination with the 
amphiphilic peptide GALA to the formulation would displace the bound siRNA. As can be 
seen in Figure 1a, naked siRNA (i) has migrated through the gel, but for the three formulations 
tested (i.e. CCD, CD-F-G and CD-M-G), there was no siRNA band detected, highlighting that 
in these cases, siRNA is bound by the CD complexes. This result confirms that all three 
complexes were capable of binding siRNA efficiently. 
The potential for the nanoparticles to aggregate in a salt-containing medium was also 
investigated. The addition of PEG is used to confer “steric” stability to nanoparticles (Gref et 
al., 2000; Monfardini and Veronese, 1998). Recent studies have shown that incorporation of 
PEG of various lengths (500, 1000, 2000 and 5000) increases the stability of cyclodextrin 
containing nanoparticles and increased the t1/2 of siRNA in vivo (Evans et al., 2016b; Godinho 
et al., 2014b). The diameter of CCD and CD-F-G (measured by dynamic light scattering (DLS)) 
was determined over a 24 h period following the addition of optiMEM® (Figure 1 b). In the 
case of unPEGylated CCD, there was a dramatic increase in the particle size to approximately 
850 nm and 1600 nm at 4 and 24 hours respectively. This implies that the CCD formulation is 
not stable in salt-containing media, which was previously reported (O'Mahony et al., 2013). In 
contrast, CD-F-G nanoparticles maintained a particle size of less than 200 nm over the 24 hour 
period (Figure 1 b). The stability of PEGylated CD nanoparticles in salt-containing media has 
been previously reported, where complexes maintained their particle size in optiMEM® for up 
to 48 h (Evans et al., 2016b). 
siRNA is subject to degradation and it is important that any vector designed for its delivery is 
capable of protecting its cargo from endogenous nucleases (Wittrup and Lieberman, 2015) . 
Thus CD-F-G and CD-M-G complexes were incubated in 10 % FBS and siRNA stability was 
monitored for up to 8 h. We previously reported that in the presence of FBS, free siRNA 
degraded in a few minutes (Evans et al., 2016b). In contrast, the presence of cyclodextrin plus 
PEG was capable of protecting siRNA from serum nucleases for up to 8 h (Figure 1 c).  
The morphology of the targeted formulation (i.e. CD-F-G) was determined by TEM (Figure 1 
d). CD-F-G gave uniform, spherical nanoparticles of approximately 200 nm in size, which 
reflects the results obtained by DLS (Table 1). DSPE-PEG5000 post-inserted into preformed 
amphiphilic CD.siRNA nanoparticles has previously been shown to result in a more spherical 
structure (Evans et al., 2016b).  
3.2 CD-F-G Nanoparticles displayed folate-mediated uptake, a low cytotoxic 
profile and specific knockdown of the luciferase reporter gene in vitro. 
Due to the heterogeneous nature of cancer, patients will respond differently to the same 
treatments and advances in genomics has allowed for the personalised treatment of patients 
based on the biology of their tumours (Van't Veer and Bernards, 2008). Two approaches are 
commonly utilised to target solid tumours: active targeting and passive accumulation, with both 
strategies showing promise at the preclinical and clinical trial stage (Sagnella et al., 2014). 
While passive accumulation is dependent on exploiting the properties of the tumour 
microenvironment (such as “leaky vasculature”), active targeting utilises a targeting ligand to 
exploit the overexpression of certain receptors on the surface of tumour cells (Cho et al., 2008; 
Lammers et al., 2008; Lammers et al., 2012). 
A common targeting ligand that has been exploited for the development of cancer therapy is 
folate (Zwicke et al., 2012). In this study, the uptake of CD-F-G and CD-M-G nanoparticles 
was assessed in prostate cancer cell lines PC3 and LNCaP cells. For both cell lines, a significant 
increase (p<0.05) in the uptake of the targeted CD-F-G compared with untargeted CD-M-G 
NPs (Figure 2a and 2b) was observed. In addition, a competition assay using excess free folate 
(2.5 mM) resulted in significant reductions (p<0.01) in the uptake of CD-F-G (44 % for PC3 
and 65 % for LNCaP at 4 h). No difference in uptake was observed for CD-M-G. These results 
taken together would indicate that the uptake of the targeted nanoparticles is mediated (to at 
least some degree), by the folate ligand. Previous studies have shown that folate-targeted 
nanoparticles show increased uptake in both LNCaP and PC3 cells (de Oliveira et al., 2016; 
Evans et al., 2016b; Hattori and Maitani, 2005; Singh et al., 2009; Zhao et al., 2010). These 
studies highlight the benefit of targeting nanoparticles with folate for the treatment of prostate 
cancer.   
However, the uptake of folate-targeted nanoparticles in prostate cancer can be via multiple 
mechanisms. The uptake of folate nanoparticles in LNCaP cells is thought to be mediated 
primarily by the prostate specific membrane antigen (PSMA) (Pinto et al., 1996). PSMA is a 
membrane bound glycoprotein, the expression of which increases as prostate cancer progresses 
(Evans et al., 2016a). Another advantage of targeting PSMA for prostate cancer, is that it is 
rapidly internalised and recycled, meaning that high concentrations of therapeutic payload can 
be delivered to PSMA-positive cells (Behnam Azad et al., 2015). Interestingly, it has been 
shown that PC3 cells lack PSMA expression and so uptake in these cells is suggested to be 
mediated by the reduced folate carrier (RFC), a ubiquitously expressed membrane transport 
system responsible for transport of folates into mammalian cells and tissues (Hattori and 
Maitani, 2004; Matherly and Hou, 2008). The results in figure 2a and 2b highlight the folate-
specific uptake of CD-F-G into PC3 and LNCaP cells. 
In order to be applicable for therapeutic applications, it is critical that nanoparticles are assessed 
for any cytotoxic effects (Lewinski et al., 2008). None of the three CD formulations used in 
this study elicited significant levels of cytotoxicity in either LNCaP or PC3 cells compared 
with untreated controls, as analysed using the MTT assay (Figure 2c and 2d). The amphiphilic 
CD has previously been shown to be non-toxic in PC3 prostate cancer cells (Evans et al., 2015).  
In contrast, Lipofectamine 2000 (LIPO) resulted in significant levels of cytotoxicity in both 
cell lines tested over a 24 h period (p<0.001). While Lipofectamine 2000 has previously been 
shown to be a highly effective transfection agent, its use in vivo is limited by its toxicity 
(Godinho et al., 2014a). 
CD-F, CD-F-G and CD-M-G formulations complexed with luciferase siRNA were used to 
silence a luciferase reporter gene in PC3Luc cells (Figure 3). While there was a significant level 
of knockdown for the CD-F formulation (55.91 ± 6.96 %), the addition of GALA to the 
formulation (i.e. CF-F-G) significantly increased (P<0.05) the level of knockdown to 76.99 ± 
10.89 %. Delivery of luciferase siRNA using CD-F-G resulted in a similar level of knockdown 
to the positive control, Lipofectamine2000. Furthermore, there was a significantly greater level 
of luciferase knockdown by CD-F-G complexes compared to the CD-M-G formulation 
(p<0.001) demonstrating the effectiveness of folate-targeted nanoparticle delivery. Together, 
these results demonstrate the effectiveness of including PEG-Folate and GALA in the 
formulation and CD-F-G was chosen for further functional studies. 
3.3 CD-F-G Nanoparticles resulted in specific knockdown of NRP-1 and ZEB1 
and a more compact spherical structure in PC3 3D tumour spheroids. 
For the therapeutic application of RNAi, the choice of target gene is critical. For the present 
study, two genes of interest were targeted; ZEB1 and NRP1. Figure 4 displays the RT-PCR 
and western blot analysis of PC3 cells treated with CD-F-G and CD-M-G complexed with 
negative control, ZEB1 or NRP1 siRNA. CD-F-G resulted in a significant reduction in the 
levels of NRP1 mRNA (Figure 4a) (P<0.05) and ZEB1 mRNA (Figure 4c) (P<0.001) with 
reductions of 50 % and 60 % respectively. While CD-M-G did show significant knockdown of 
ZEB1 (Figure 4c) (p<0.001), CD-F-G displayed a significantly superior level of knockdown 
(P<0.05). For functional studies, it is imperative that the genes are silenced at both the mRNA 
and protein levels. Using densitometry analysis, there was an approximate 60 % and 50 % 
reduction in NRP1 (Figure 4b) and ZEB1 (Figure 4d) protein levels, respectively, in PC3 cells 
treated with CD-F-G. In contrast, when treated with CD-M-G, NRP1 (Figure 4b) and ZEB1 
(Figure 4d) protein levels fell by 30 % and less than 5 % respectively.   
Several studies have shown that folate-targeted siRNA loaded formulations perform better in 
prostate cancer cell lines and tumours compared to untargeted controls. In a recent study, a 
PSA-responsive, folate-targeted liposomal formulation administered intravenously resulted in 
a significant knockdown of PLK1 mRNA and protein, resulting in significant tumour 
regression in a 22Rv1 xenograft tumour model (Xiang et al., 2013). Folate-targeted gold 
nanoparticles have been shown to result in a significant reduction in RelA mRNA in LNCaP 
cells, with untargeted controls displaying negligible levels of mRNA knockdown (Guo et al., 
2016). A folate-targeted cyclodextrin formulation was recently shown to significantly reduce 
the levels of RelA mRNA in two PSMA expressing prostate cancer cell lines; LNCaP and 
VCaP (Evans et al., 2016b). 
The combined results of the RT-PCR and western blot (Figure 4) highlight the superior 
silencing ability of the folate targeted CD (CD-F-G) over the untargeted control (i.e. CD-M-
G) in silencing therapeutically relevant genes in prostate cancer cell lines. 
To ascertain whether therapeutic efficacy was achieved, functional studies were performed 
using a 3D Matrigel™ culture to assess whether the targeted formulations complexed with 
NRP1 and ZEB1 siRNA reduced the infiltration of prostate cancer cells into a Matrigel™ layer 
(Figure 5). Figure 5a shows a representative phase contrast image of PC3 spheroids 3-4 days 
following their culture onto Matrigel™, prior to any treatment with either CD-F-G or CD-M-
G. Cultures treated with CD-F-G complexes resulted in more compact non-invasive colonies 
compared with the respective negative controls (Figure 5b). Interestingly, the CD-M-G 
complexes with NRP1 and ZEB1 siRNA did not result in a change in the invasive phenotype 
of the PC3 cells (Figure 5b), perhaps due to the inferior level of knockdown of the target 
protein compared with CD-F-G. 
These results are consistent with previously published data. ZEB1 is a well-studied marker of 
epithelial to mesenchymal transition (EMT). The silencing of ZEB1 in a subpopulation of PC3 
cells selected for their efficient transendothelial migration resulted in an upregulation of E-
cadherin and a reduction in transendothelial migration (Drake et al., 2009). A lot of research 
studies have demonstrated that the EMT process is integral for the metastasis of many different 
carcinoma types (Heerboth et al., 2015; Hugo et al., 2007), which has highlighted the potential 
therapeutic benefit for silencing ZEB1 in these cancers. For example, the knockdown of ZEB1 
by siRNA significantly reduces the invasion of H460 lung cancer cells in vitro and significantly 
reduces the number of lung metastases in vivo (Fang et al., 2014). A recent study showed that 
the transfection of HCC827 lung adenocarcinoma cells resulted in significantly less cells 
migrating through a transwell chamber (Zhang et al., 2013). Similarly the transfection of gastric 
adenocarcinoma AGS cells with ZEB1 siRNA significantly reduced the number of invasive 
colonies (Jia et al., 2012). In addition, ZEB1 siRNA was also capable of reducing the invasive 
activity of NOZ gallbladder cancer cells (Adachi et al., 2009). 
NRP1 is another viable therapeutic target for metastatic cancer therapy. Anti-NRP1 therapy 
resulted in reduced VEGF-induced migration and in vivo neovascularization in HUVEC cells 
(Pan et al., 2007). For medulloblastoma, the blockade of the placental growth factor 
(PIGF)/NRP1 pathway result in antitumour effects in vivo, tumour regression, decreased 
metastasis and increased mouse survival (Snuderl et al., 2013). The inhibition of NRP1 (either 
by inhibitor or NRP1 siRNA) reduced the migration of A549 and ACHN cells and also 
increased the sensitivity of the prostate cancer cell line DU145 to cisplatin and 5-FU (Jia et al., 
2010). The stable knockdown of NRP1 in PC3 cells has also been shown to result in a less 
invasive cancer cell phenotype (Tse et al., 2017).  
Conclusion 
Metastatic prostate cancer still has very few treatment options, with current therapies offering 
only very modest increases in overall survival. In the present study, a folate-targeted modified 
CD-based siRNA delivery vector has been formulated with an amphiphilic fusogenic peptide, 
GALA, to aid in endosomal escape. The formulation is capable of binding and protecting 
siRNA from serum nucleases and the nanoparticles are capable of resisting aggregation for up 
to 24 h in salt-containing medium. The nanoparticles show folate-mediated uptake in two 
prostate cancer cell lines with reported different folate uptake mechanisms (Hattori and 
Maitani, 2004, 2005). Folate-targeted complexes show specific knockdown of a luciferase 
reporter gene and two target genes (NRP1 and ZEB1) in the metastatic prostate cancer PC3 
cell line. Initial functional studies of PC3 tumour spheroids have shown that knockdown of 
NRP1 and ZEB1 by CD-F-G resulted in more compact colonies and reduced infiltration into 
the underlying Matrigel™ layer. To our knowledge, this is the first example of a folate-targeted 
CD vector used to silence therapeutically relevant genes in a 3D tumour spheroid model of 
prostate cancer. 
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Figure Legends 
Figure 1. Assessment of CD complexes in media and morphology of CD.siRNA structures 
by TEM; a) siRNA binding assay with i) naked siRNA, ii) CCD, iii) CD-F-G and iv) CD-M-G. 
Naked siRNA (i) has migrated through the gel. However for the three formulations tested, the 
siRNA did not migrate through the well, highlighting that it is bound by the CD complexes b) 
Stability of CCD and CD-F-G nanoparticles in 90 % optiMEM® over 24 h, c) Stability of CD-
F-G (top) and CD-M-G (bottom) in 10 % FBS. d) TEM images of CD-F-G; magnification 
x100k scale 200nm  
Figure 2: Competitive uptake of cyclodextrin nanoparticles and comparing cytotoxicity of 
cyclodextrin nanoparticles and Lipofectamine 2000 in PC3 and LNCaP cells: Uptake of 6-
FAM-labelled siRNA (50 nM) into a) PC3 and b) LNCaP cells either with no pre-treatment or 
pre-treated with 2.5 mM free folic acid 1 h prior to transfection. Uptake of CD-F-G 
nanoparticles was significantly reduced in the presence of free folic acid. Toxicity of CD 
nanoparticles was assessed by MTT 24 h following treatment in c) PC3 and d) LNCaP cells. 
Figure 3: Knockdown of luciferase reporter gene in PC3 cells by Lipofectamine2000 (LIPO), 
targeted (CD-F-G, CD-F) and untargeted complexes (CD-M-G). Luciferase gene knockdown 
by Lipofectamine2000 and Cyclodextrin nanoparticles was normalised to the respective siRNA 
negative control counterpart. CD-F-G nanoparticles complexed with luciferase siRNA resulted 
in a significant level of luciferase knockdown compared to both CD-M-G and CD-F. Data are 
presented as mean ± SD (***p<0.001, n=3). 
Figure 4: CD-F-G complexed with ZEB1 and NRP1 siRNA results in significant levels of 
mRNA and protein knockdown assessed by RT-PCR and western blot in PC3 cells. Following 
transfection of PC3 cells with cyclodextrin nanoparticles complexed with NRP1 or ZEB1 
siRNA, the relative mRNA knockdown and protein suppression levels were confirmed by RT-
PCR (a, c) and western blot analysis (b, d). For CD formulations, knockdown was compared 
with its equivalent non-silencing control (*p<0.05, ***p<0.001). Data are presented as mean 
± SD (n=4-6). 
Figure 5: Representative phase-contrast images of PC3 cells grown in a 3D Matrigel™ 
culture at 96 h post treatment.  Representative images of PC3 spheroids prior to treatment a), 
PC3 spheroids were treated with either b) CD-F-G or c) CD-M-G complexed with non-
silencing, NRP1 or ZEB1 siRNA at t= 96 h (scale bar=100 μM). The silencing of NRP1 and 
ZEB1 by CD-F-G complexes result in more compact, spherical colonies compared to non-
silencing controls and CD-M-G controls 
Table Legends 
Table 1. Size and charge of CD.siRNA complexes. Physicochemical properties of CD.siRNA 
complexes with the incorporation of DSPE-PEG5000 and the amphiphilic peptide GALA by the 
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CCD 1:0:0:0 202.76 ± 20.41 
0.33 ± 
0.04 
46.42 ± 1.67 
CD-M-G 1:0:0.75:0.05 128.66 ± 10.31 
0.23 ± 
0.02 
-9.07 ± 1.31 
CD-F 1:0.75:0:0 154.5 ± 35.79 
0.26 ± 
0.07 
30.32 ± 2.44 
CD-F-G 1:0.75:0:0.05 187.99  ± 10.02 
0.13  ± 
0.06 
0.67  ± 2.66 
 
 
